[ banner - AUA NEWS ]


Wendy Isett, AUA
410-977-4770, Wisett@auanet.org


Urges providers to incorporate patient treatment goals, preferences and personal goals

SAN DIEGO, CA (May 6, 2013) – Metastatic, castration-resistant prostate cancer (mCRPC) remains an incurable disease, but new treatments –including immunotherapeutic, chemotherapeutic agents, anti-androgens and androgen synthesis inhibitors – may improve outcomes in certain patients, according to a new clinical guideline released today by the American Urological Association (AUA) during its 2013 Annual Meeting in San Diego, CA.

Over the past decade, a number of new treatments have emerged to improve survival in men whose prostate cancer is not responsive to traditional androgen deprivation therapy. However, clinical decision-making for patients with mCRPC is complex, due to the multiple options available for treatment and proper sequencing of these medications in patients. The guideline provides a sound, evidence-based rationale for the treatment of CRPC, but urges practitioners to use the guidance in conjunction with current literature and the individual patient’s treatment goals.

Guidelines statements are specific to six different index patients, identified based on symptoms, performance status, the presence or absence of metastases and whether or not docetaxel has been administered.

Index Patient 1: Asymptomatic, non-metastatic CRPC

Index Patient 2: Asymptomatic or minimally symptomatic, mCRPC without prior docetaxel chemotherapy

Index Patient 3: Symptomatic, mCRPC with good performance status and no prior chemotherapy

Index Patient 4: Symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy

Patient 5: Symptomatic, mCRPC with good performance status and prior doxetaxel chemotherapy

Index Patient 6: Symptomatic, mCRPC with poor performance status and prior docetaxel chemotherapy

Because the most common site for prostate cancer metastasis is the skeletal system, the guideline also makes key statements regarding bone health in patients with mCRPC:

"Prostate cancer death are typically the result of mCRPC, a painful disease for which, until recently, the only treatments available were palliative," said Dr. Michael Cookson, who chaired the panel that developed the guideline. "In recent years, a number of new treatments and therapeutic agents have entered the market that have been shown to minimize adverse effects and pain and prolong survival in some patients, but the fact remains that mCRPC is the terminal stage of prostate cancer.

"As research continues in this area, we are hopeful that new developments will lead us closer to preventing the development of mCRPC."

NOTE TO REPORTERS: Expert spokespeople are available to discuss the AUA’s new Guideline on Castration Resistant Prostate Cancer. Please contact the Communications Office at 410-689-3932 for more information or to arrange an interview.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 19,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.